Stay updated on Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial

Sign up to get notified when there's something new on the Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study involving the evaluation of the safety, pharmacokinetics, and antiviral effects of Galidesivir in subjects with Yellow Fever or COVID-19.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:47.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    38%
    Check dated 2024-05-22T21:12:24.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:29:23.000Z thumbnail image

Stay in the know with updates to Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial page.